Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) has been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.
Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Eyegate Pharmaceuticals in a report on Tuesday, October 25th.
An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 386,940 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,002,000. Sabby Management LLC owned about 4.64% of Eyegate Pharmaceuticals at the end of the most recent quarter.
Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.50 on Tuesday. Eyegate Pharmaceuticals has a 12-month low of $1.31 and a 12-month high of $5.10. The stock has a 50 day moving average of $1.63 and a 200-day moving average of $2.44. The company’s market capitalization is $13.43 million.